vs
Side-by-side financial comparison of BTCS Inc. (BTCS) and MAXCYTE, INC. (MXCT). Click either name above to swap in a different company.
BTCS Inc. is the larger business by last-quarter revenue ($7.1M vs $4.8M, roughly 1.5× MAXCYTE, INC.). On growth, BTCS Inc. posted the faster year-over-year revenue change (205.5% vs -20.9%). MAXCYTE, INC. produced more free cash flow last quarter ($-2.9M vs $-9.8M). Over the past eight quarters, BTCS Inc.'s revenue compounded faster (296.4% CAGR vs -7.4%).
MaxCyte Inc. is a global biotechnology company focused on developing cell engineering platforms and enabling technologies for cell and gene therapy advancement. Its proprietary non-viral cell modification systems are widely used by pharmaceutical, biotech and life science research entities to develop immunotherapies, gene-edited treatments and next-generation biologic drugs from preclinical research through commercialization.
BTCS vs MXCT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.1M | $4.8M |
| Net Profit | — | $-9.6M |
| Gross Margin | 12.4% | — |
| Operating Margin | — | -234.5% |
| Net Margin | — | -200.5% |
| Revenue YoY | 205.5% | -20.9% |
| Net Profit YoY | — | 9.4% |
| EPS (diluted) | $-1.58 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.1M | $4.8M | ||
| Q3 25 | $4.9M | $4.6M | ||
| Q2 25 | $2.8M | $5.8M | ||
| Q1 25 | $1.7M | $5.7M | ||
| Q4 24 | $2.3M | $6.1M | ||
| Q3 24 | $739.2K | $5.6M | ||
| Q2 24 | $561.2K | $5.0M | ||
| Q1 24 | $451.4K | $5.6M |
| Q4 25 | — | $-9.6M | ||
| Q3 25 | $65.6M | $-12.4M | ||
| Q2 25 | $3.9M | $-12.4M | ||
| Q1 25 | $-17.3M | $-10.3M | ||
| Q4 24 | — | $-10.6M | ||
| Q3 24 | $-9.0M | $-11.6M | ||
| Q2 24 | $-6.7M | $-9.4M | ||
| Q1 24 | $12.3M | $-9.5M |
| Q4 25 | 12.4% | — | ||
| Q3 25 | 22.0% | — | ||
| Q2 25 | -2.9% | — | ||
| Q1 25 | 7.1% | — | ||
| Q4 24 | 2.9% | — | ||
| Q3 24 | 26.5% | — | ||
| Q2 24 | 69.9% | — | ||
| Q1 24 | 64.4% | — |
| Q4 25 | — | -234.5% | ||
| Q3 25 | — | -307.4% | ||
| Q2 25 | — | -244.3% | ||
| Q1 25 | — | -214.1% | ||
| Q4 24 | — | -213.1% | ||
| Q3 24 | — | -250.4% | ||
| Q2 24 | — | -241.0% | ||
| Q1 24 | — | -219.8% |
| Q4 25 | — | -200.5% | ||
| Q3 25 | 1328.1% | -269.7% | ||
| Q2 25 | 140.0% | -212.2% | ||
| Q1 25 | -1022.5% | -178.7% | ||
| Q4 24 | — | -175.0% | ||
| Q3 24 | -1223.0% | -205.9% | ||
| Q2 24 | -1198.9% | -188.8% | ||
| Q1 24 | 2715.3% | -170.6% |
| Q4 25 | $-1.58 | — | ||
| Q3 25 | $1.30 | $-0.12 | ||
| Q2 25 | $0.14 | $-0.12 | ||
| Q1 25 | $-0.86 | — | ||
| Q4 24 | $0.28 | — | ||
| Q3 24 | $-0.56 | $-0.11 | ||
| Q2 24 | $-0.43 | $-0.09 | ||
| Q1 24 | $0.63 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.5M | $103.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.4M | $171.5M |
| Total Assets | $214.6M | $202.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.5M | $103.0M | ||
| Q3 25 | $4.5M | $105.7M | ||
| Q2 25 | $639.2K | $126.6M | ||
| Q1 25 | $269.9K | $138.3M | ||
| Q4 24 | $2.0M | $154.5M | ||
| Q3 24 | $254.5K | $153.8M | ||
| Q2 24 | $536.7K | $157.3M | ||
| Q1 24 | $670.6K | $157.5M |
| Q4 25 | $139.4M | $171.5M | ||
| Q3 25 | $225.4M | $180.3M | ||
| Q2 25 | $31.1M | $190.7M | ||
| Q1 25 | $20.6M | $199.4M | ||
| Q4 24 | $34.0M | $206.3M | ||
| Q3 24 | $25.2M | $213.3M | ||
| Q2 24 | $33.1M | $221.3M | ||
| Q1 24 | $39.3M | $226.4M |
| Q4 25 | $214.6M | $202.5M | ||
| Q3 25 | $298.9M | $213.5M | ||
| Q2 25 | $40.8M | $219.8M | ||
| Q1 25 | $21.0M | $230.0M | ||
| Q4 24 | $38.2M | $239.5M | ||
| Q3 24 | $26.5M | $248.6M | ||
| Q2 24 | $33.8M | $251.5M | ||
| Q1 24 | $39.5M | $257.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-9.8M | $-2.7M |
| Free Cash FlowOCF − Capex | $-9.8M | $-2.9M |
| FCF MarginFCF / Revenue | -138.1% | -61.0% |
| Capex IntensityCapex / Revenue | 0.2% | 4.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-15.8M | $-36.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-9.8M | $-2.7M | ||
| Q3 25 | $-2.8M | $-7.5M | ||
| Q2 25 | $-1.3M | $-9.9M | ||
| Q1 25 | $-1.9M | $-14.4M | ||
| Q4 24 | $-3.5M | $-7.8M | ||
| Q3 24 | $-695.2K | $-4.4M | ||
| Q2 24 | $-924.1K | $-4.8M | ||
| Q1 24 | $-769.0K | $-10.6M |
| Q4 25 | $-9.8M | $-2.9M | ||
| Q3 25 | $-2.8M | $-7.8M | ||
| Q2 25 | $-1.3M | $-10.4M | ||
| Q1 25 | $-1.9M | $-15.1M | ||
| Q4 24 | $-3.5M | $-8.0M | ||
| Q3 24 | — | $-4.8M | ||
| Q2 24 | — | $-5.1M | ||
| Q1 24 | — | $-11.4M |
| Q4 25 | -138.1% | -61.0% | ||
| Q3 25 | -56.7% | -168.5% | ||
| Q2 25 | -48.2% | -179.2% | ||
| Q1 25 | -112.7% | -262.3% | ||
| Q4 24 | -152.2% | -131.6% | ||
| Q3 24 | — | -85.5% | ||
| Q2 24 | — | -103.3% | ||
| Q1 24 | — | -203.6% |
| Q4 25 | 0.2% | 4.8% | ||
| Q3 25 | 0.1% | 6.5% | ||
| Q2 25 | 0.1% | 10.0% | ||
| Q1 25 | 0.1% | 11.4% | ||
| Q4 24 | 0.1% | 2.4% | ||
| Q3 24 | — | 7.2% | ||
| Q2 24 | — | 5.9% | ||
| Q1 24 | — | 14.4% |
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | -0.34× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.06× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BTCS
| Builder Plus | $5.9M | 83% |
| Other | $1.2M | 17% |
MXCT
| Products | $4.2M | 87% |
| Other | $634.0K | 13% |
